Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002389547 | SCV002701789 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-10-26 | criteria provided, single submitter | clinical testing | The p.L471* variant (also known as c.1412T>A), located in coding exon 10 of the CTNNA1 gene, results from a T to A substitution at nucleotide position 1412. This changes the amino acid from a leucine to a stop codon within coding exon 10. This alteration is expected to result in premature protein truncation or nonsense-mediated mRNA decay. However, the gene-disease association for CTNNA1 is limited. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003546821 | SCV004260427 | pathogenic | not provided | 2023-12-30 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu471*) in the CTNNA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CTNNA1 are known to be pathogenic (PMID: 32051609, 34425242). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CTNNA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1772070). For these reasons, this variant has been classified as Pathogenic. |